BioSpace News Archive

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.

Invitae Corporation, a leading medical genetics company, announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Proceeds to expand Contract Development and Manufacturing Organization (CDMO) capacity to deliver GMP adeno-associated viruses (AAV) product for clients by mid-2021 and to develop a proprietary pipeline of novel gene therapies

Trinseo, a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber, announced the release of its 2020 Sustainability & Corporate Social Responsibility Report.

Changed primary endpoint to continuous from current responder endpoint, in-line with recent FDA guidance and very similar to IW-3718 Phase IIb trial

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological products, issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.

50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial Subject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III part of the trial will be initiated Primary endpoint of the planned Phase III part to be 28-day all-cause mortality

Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122 against coronavirus.

- Multiple System Atrophy (MSA) is a rare, relentlessly progressive and fatal neurodegenerative disease - Verdiperstat is a potential first-in-class, brain-penetrant inhibitor of myeloperoxidase (MPO), an enzyme implicated in neuroinflammation and neurodegeneration - Approximately 300 patients enrolled in the 48-week trial and topline data anticipated by the end of 2021 [21-July-2020]